Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 38

1.

Alternative splicing and cell survival: from tissue homeostasis to disease.

Paronetto MP, Passacantilli I, Sette C.

Cell Death Differ. 2016 Dec;23(12):1919-1929. doi: 10.1038/cdd.2016.91. Review.

PMID:
27689872
2.

Modulation of Bcl-x Alternative Splicing Induces Apoptosis of Human Hepatic Stellate Cells.

Wu L, Mao C, Ming X.

Biomed Res Int. 2016;2016:7478650. doi: 10.1155/2016/7478650.

3.

Splice-switching antisense oligonucleotides as therapeutic drugs.

Havens MA, Hastings ML.

Nucleic Acids Res. 2016 Aug 19;44(14):6549-63. doi: 10.1093/nar/gkw533.

4.

The Splicing Efficiency of Activating HRAS Mutations Can Determine Costello Syndrome Phenotype and Frequency in Cancer.

Hartung AM, Swensen J, Uriz IE, Lapin M, Kristjansdottir K, Petersen US, Bang JM, Guerra B, Andersen HS, Dobrowolski SF, Carey JC, Yu P, Vaughn C, Calhoun A, Larsen MR, Dyrskjøt L, Stevenson DA, Andresen BS.

PLoS Genet. 2016 May 19;12(5):e1006039. doi: 10.1371/journal.pgen.1006039.

5.

The RNA helicase A in malignant transformation.

Fidaleo M, De Paola E, Paronetto MP.

Oncotarget. 2016 May 10;7(19):28711-23. doi: 10.18632/oncotarget.7377. Review.

6.

Mcl-1 involvement in mitochondrial dynamics is associated with apoptotic cell death.

Morciano G, Giorgi C, Balestra D, Marchi S, Perrone D, Pinotti M, Pinton P.

Mol Biol Cell. 2016 Jan 1;27(1):20-34. doi: 10.1091/mbc.E15-01-0028.

7.

Splicing Regulation: A Molecular Device to Enhance Cancer Cell Adaptation.

Pagliarini V, Naro C, Sette C.

Biomed Res Int. 2015;2015:543067. doi: 10.1155/2015/543067. Review.

8.

SAM68: Signal Transduction and RNA Metabolism in Human Cancer.

Frisone P, Pradella D, Di Matteo A, Belloni E, Ghigna C, Paronetto MP.

Biomed Res Int. 2015;2015:528954. doi: 10.1155/2015/528954. Review.

9.
10.

Dendritic nanoconjugates for intracellular delivery of neutral oligonucleotides.

Ming X, Wu L, Carver K, Yuan A, Min Y.

Nanoscale. 2015 Aug 7;7(29):12302-6. doi: 10.1039/c5nr01665g.

11.

Direct oligonucleotide-photosensitizer conjugates for photochemical delivery of antisense oligonucleotides.

Yuan A, Laing B, Hu Y, Ming X.

Chem Commun (Camb). 2015 Apr 18;51(30):6678-80. doi: 10.1039/c5cc00573f.

12.

Group VIA Phospholipase A2 (iPLA2β) Modulates Bcl-x 5'-Splice Site Selection and Suppresses Anti-apoptotic Bcl-x(L) in β-Cells.

Barbour SE, Nguyen PT, Park M, Emani B, Lei X, Kambalapalli M, Shultz JC, Wijesinghe D, Chalfant CE, Ramanadham S.

J Biol Chem. 2015 Apr 24;290(17):11021-31. doi: 10.1074/jbc.M115.648956.

13.

High-throughput screening identifies small molecules that enhance the pharmacological effects of oligonucleotides.

Yang B, Ming X, Cao C, Laing B, Yuan A, Porter MA, Hull-Ryde EA, Maddry J, Suto M, Janzen WP, Juliano RL.

Nucleic Acids Res. 2015 Feb 27;43(4):1987-96. doi: 10.1093/nar/gkv060.

14.

Antisense Modulation of RNA Processing as a Therapeutic Approach in Cancer Therapy.

Spraggon L, Cartegni L.

Drug Discov Today Ther Strateg. 2013 Fall;10(3):e139-e148.

15.

Regulation of BCL-X splicing reveals a role for the polypyrimidine tract binding protein (PTBP1/hnRNP I) in alternative 5' splice site selection.

Bielli P, Bordi M, Di Biasio V, Sette C.

Nucleic Acids Res. 2014 Oct 29;42(19):12070-81. doi: 10.1093/nar/gku922.

16.

The splicing factor RBM4 controls apoptosis, proliferation, and migration to suppress tumor progression.

Wang Y, Chen D, Qian H, Tsai YS, Shao S, Liu Q, Dominguez D, Wang Z.

Cancer Cell. 2014 Sep 8;26(3):374-89. doi: 10.1016/j.ccr.2014.07.010.

17.

Long non-coding RNA INXS is a critical mediator of BCL-XS induced apoptosis.

DeOcesano-Pereira C, Amaral MS, Parreira KS, Ayupe AC, Jacysyn JF, Amarante-Mendes GP, Reis EM, Verjovski-Almeida S.

Nucleic Acids Res. 2014 Jul;42(13):8343-55. doi: 10.1093/nar/gku561. Erratum in: Nucleic Acids Res. 2016 Nov 2;44(19):9518.

18.

The transcription factor FBI-1 inhibits SAM68-mediated BCL-X alternative splicing and apoptosis.

Bielli P, Busà R, Di Stasi SM, Munoz MJ, Botti F, Kornblihtt AR, Sette C.

EMBO Rep. 2014 Apr;15(4):419-27. doi: 10.1002/embr.201338241.

19.

Oncogenic alternative splicing switches: role in cancer progression and prospects for therapy.

Bonomi S, Gallo S, Catillo M, Pignataro D, Biamonti G, Ghigna C.

Int J Cell Biol. 2013;2013:962038. doi: 10.1155/2013/962038. Review.

20.

Alternative splicing programs in prostate cancer.

Sette C.

Int J Cell Biol. 2013;2013:458727. doi: 10.1155/2013/458727.

Items per page

Supplemental Content

Support Center